GET DAILY SIGNALSEli Lilly (LLY) Delivers Solid Q3 2026 Results on Continued Metabolic Growth
Key Takeaways
- Eli Lilly reported third-quarter 2026 revenue of $24.4 billion, up roughly 39% year over year and above Wall Street consensus estimates.
- Non-GAAP (adjusted) earnings per share reached $7.48, a 7% increase from $7.02 a year earlier, while reported diluted EPS from continuing operations came in at $7.22.
- Mounjaro revenue climbed 65% to $10.7 billion, and Zepbound revenue rose 48% to $5.3 billion on strong demand.
- Management raised full-year 2026 revenue guidance to a range of $91 billion to $92 billion, with a midpoint of $91.5 billion.
- Full-year adjusted EPS guidance was trimmed to $35.00–$36.00, largely reflecting $4.57 per share in acquired in-process research and development (IPR&D) charges.
- Shares advanced in early trading following the release as investors responded to the stronger-than-expected top line and raised outlook.
- For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
- Discover timely trade ideas with Trending AI Robots.
Earnings Context and Its Significance
Eli Lilly's third-quarter 2026 report serves as an important checkpoint for a company whose expansion is now heavily tied to its diabetes and obesity treatments. The market has been monitoring whether Mounjaro and Zepbound can maintain their momentum while newer offerings such as Foundayo begin to scale. After a stretch of rapid revenue increases, these results gave investors a clearer picture of demand patterns, pricing trends, and the effects of substantial spending on research, production, and acquisitions. The quarter also carried broader signals for the weight-loss and metabolic-health sector, where LLY competes in one of the most dynamic areas of biopharma.
Reported Results
LLY posted third-quarter 2026 revenue of $24.4 billion, an increase of about 39% from $17.6 billion in the prior-year period and ahead of analyst consensus. Non-GAAP earnings per share came in at $7.48, up 7% from $7.02 a year earlier, while reported diluted EPS from continuing operations was $7.22 compared with $6.21 in the year-ago quarter. Net income rose to approximately $6.45 billion from $5.58 billion.
Growth was driven primarily by the metabolic portfolio. Mounjaro revenue increased 65% to $10.7 billion, while Zepbound revenue grew 48% to $5.3 billion, both supported by strong volume. Gross margin as a percentage of revenue improved, and the company's non-GAAP performance margin reached 54.2%, up 5.9 percentage points year over year. The quarter also included roughly $900 million of benefits from milestone payments and favorable adjustments to rebate and discount estimates.
Management raised its full-year 2026 revenue outlook to $91 billion–$92 billion, up from a prior range of $85 billion–$87 billion. At the same time, full-year adjusted EPS guidance was lowered to $35.00–$36.00 from $35.50–$36.50, reflecting $4.57 per share of acquired IPR&D charges from recent business development activity. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Shares of LLY rose in premarket and early trading following the announcement, climbing several percentage points as investors focused on the top-line beat and the raised revenue outlook. The upward move reflected relief that demand for Mounjaro and Zepbound remained robust and that management saw enough momentum to lift its full-year sales forecast. Sentiment was tempered somewhat by the reduced adjusted EPS guidance, which stemmed primarily from non-recurring acquired IPR&D charges tied to business development rather than weakening operations. Heading into the report, expectations were high, and the market interpreted the results as confirmation that Lilly's core growth engine remains intact even as it absorbs heavy investment.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching whether LLY can sustain the volume growth in its diabetes and obesity portfolio while managing pricing pressure, particularly in international markets and in the U.S. as rebate dynamics evolve. The global rollout of Foundayo, the company's oral GLP-1 treatment, is an important near-term catalyst, as is the progression of Retatrutide, a next-generation weight-loss candidate. Regulatory decisions and new indications across oncology, immunology, and neuroscience could also shape the growth narrative.
Cost and margin trends remain a focal point. Lilly is investing heavily in research and development, promotional activity for new launches, and a major expansion of manufacturing capacity in the U.S., all of which pressure near-term margins even as they support long-term growth. The impact of further business development deals and any associated IPR&D charges will also be worth monitoring, since these can swing reported and adjusted earnings quarter to quarter.
Finally, competitive dynamics in the metabolic-health market will matter. With rivals advancing their own treatments, the pace of patient uptake, market share, and pricing across Lilly's key products will be central to whether the company can build on this quarter's momentum without sacrificing profitability.
Enhancing My Research with Tickeron Tools
In my own work, I occasionally turn to Tickeron’s AI Screener when I want to quickly compare a stock like LLY against peers on technical patterns, fundamentals, and AI-driven signals. It helps surface ideas and save time during earnings reviews without replacing deeper fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LLY's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for LLY turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LLY as a result. In 48 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +0.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 258 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 232 of 297 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for LLY moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 25 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
LLY broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 14 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 67 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (33.895) is slightly higher than the industry average of (-2.729). P/E Ratio (43.159) is within average values for comparable stocks, (20.997). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.040) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement